SANA BIOTECHNOLOGY INC (SANA) Stock Price, Forecast & Analysis
NASDAQ:SANA • US7995661045
SANA Key Statistics, Chart & Performance
The current stock price of SANA is 3.79 USD. In the past month the price decreased by -20.04%. In the past year, price increased by 19.94%.
SANA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SANA. When comparing the yearly performance of all stocks, SANA turns out to be only a medium performer in the overall market: it outperformed 62.36% of all stocks.
SANA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SANA. SANA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SANA Financial Highlights
Over the last trailing twelve months SANA reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 41.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.83% | ||
| ROE | -120.02% | ||
| Debt/Equity | 0 |
SANA Forecast & Estimates
15 analysts have analysed SANA and the average price target is 8.33 USD. This implies a price increase of 119.79% is expected in the next year compared to the current price of 3.79.
SANA Ownership
SANA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.67 | 390.397B | ||
| AMGN | AMGEN INC | 16.25 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.02 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.87 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.05 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.85 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SANA
Company Profile
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 194 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Company Info
SANA BIOTECHNOLOGY INC
188 East Blaine Street, Suite 400
Seattle WASHINGTON 98102 US
CEO: Steven D. Harr
Employees: 194
Phone: 12067017914
SANA BIOTECHNOLOGY INC / SANA FAQ
Can you describe the business of SANA BIOTECHNOLOGY INC?
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 194 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
What is the current price of SANA stock?
The current stock price of SANA is 3.79 USD. The price decreased by -2.32% in the last trading session.
What is the dividend status of SANA BIOTECHNOLOGY INC?
SANA does not pay a dividend.
What is the ChartMill rating of SANA BIOTECHNOLOGY INC stock?
SANA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is SANA BIOTECHNOLOGY INC (SANA) stock traded?
SANA stock is listed on the Nasdaq exchange.
What is the market capitalization of SANA stock?
SANA BIOTECHNOLOGY INC (SANA) has a market capitalization of 1.01B USD. This makes SANA a Small Cap stock.
Can you provide the upcoming earnings date for SANA BIOTECHNOLOGY INC?
SANA BIOTECHNOLOGY INC (SANA) will report earnings on 2026-03-16, after the market close.